Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yoshifumi Yamagishi is active.

Publication


Featured researches published by Yoshifumi Yamagishi.


Diagnostic Microbiology and Infectious Disease | 1995

Investigation of nosocomial respiratory infection due to Pseudomonas cepacia by Arbitrarily primed polymerase chain reaction

Hiroshi Miyawaki; Jiro Fujita; Keiichi Takigawa; Kiyoshi Negayama; Yoshifumi Yamagishi; Yasufumi Yamaji; Kazunobu Ouchi; Teruko Nakazawa; Koichi Kawanishi; Jiro Takahara

We used DNA fingerprinting by the arbitrarily primed polymerase chain reaction (AP-PCR) technique for an epidemiologic investigation of Pseudomonas cepacia nosocomial isolates obtained from patients attending our hospital. This approach was compared with conventional phenotypic typing and pulsed-field gel electrophoresis (PFGE). The patterns of gel electrophoresis of the products of AP-PCR differed significantly according to differences in the concentration of Mg2+ and in pH. AP-PCR and PFGE was identical in their resolving power, as the two methods generated four different profiles and identified the same group of strains. The AP-PCR method constitutes an easy alternative to the well-established PFGE method.


Journal of Alternative and Complementary Medicine | 2013

Synergistic effect between Juzen-taiho-to, a Japanese traditional herbal medicine, and gemcitabine single-agent chemotherapy for advanced biliary tract cancer.

Takamasa Nishiuchi; Yuichi Okutani; Yoshifumi Yamagishi; Toshikazu Fujita; Osamu Imataki; Hiroaki Ohnishi; Takuya Matsunaga; Teruki Shimizu; Hiroshi Shimizu

This is the first report of the successful treatment of advanced biliary tract cancer with gemcitabine single-agent chemotherapy in combination with Juzen-taiho-to (JTT), a Japanese traditional herbal medicine. An 84-year-old woman was referred to our hospital with general fatigue and appetite loss; she was diagnosed with advanced biliary tract cancer and accompanying colonic invasion and hepatic metastasis. The patients response to combination chemotherapy was extremely good, and her tumors disappeared. Recent studies have confirmed the occurrence of spontaneous and induced antitumor immune responses, carried out by tumor-infiltrating lymphocytes in the tumor microenvironment. The availability, antigen presentation, and proliferation of these immune cells are increased by cytokines such as granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-2. Recently, JTT has gained recognition as a biological response modifier that has stimulatory effects on systemic immune responses such as enhancement of cytokine expression (GM-CSF, IL-2, etc.). In addition, some chemotherapy agents, such as anthracyclines and gemcitabine, are effective boosters of the immune response through tumor-specific antigen overexpression after apoptotic tumor cell destruction. These findings suggest that JTT enhances the antitumor effects of gemcitabine, in particular its tumor-specific effects on immune response, and these drugs are a good combination for advanced biliary tract cancer therapy.


The Journal of the Japanese Association for Infectious Diseases | 1993

Nosocomial outbreak of Pseudomonas cepacia respiratory infection in immunocompromised patients associated with contaminated nebulizer devices.

Keiichi Takigawa; Jiro Fujita; Kiyoshi Negayama; Yoshifumi Yamagishi; Yasufumi Yamaji; Ouchi K; Yamada K; Mitsuko Abe; Teruko Nakazawa; Koichi Kawanishi


Chest | 1993

Clinical features of Pseudomonas cepacia pneumonia in an epidemic among immunocompromised patients.

Yoshifumi Yamagishi; Jiro Fujita; Keiichi Takigawa; Kiyoshi Negayama; Teruko Nakazawa; Jiro Takahara


Chest | 1992

Elevation of Plasma Truncated Elastase α1-Proteinase Inhibitor Complexes in Patients with Inflammatory Lung Diseases

Jiro Fujita; Hiroyuki Nakamura; Yoshifumi Yamagishi; Yasufumi Yamaji; Taiichi Shiotani; Shozo Irino


Journal of Antimicrobial Chemotherapy | 1992

Activity of antibiotics against resistant Pseudomonas aeruginosa

Jiro Fujita; Kiyoshi Negayama; Keiichi Takigawa; Yoshifumi Yamagishi; Akihito Kubo; Yasufumi Yamaji; Jiro Takahara


Chest | 1993

Respiratory Failure due to Pulmonary Lymphangitis Carcinomatosis

Jiro Fujita; Yoshifumi Yamagishi; Akihito Kubo; Keiichi Takigawa; Yasufumi Yamaji; Jiro Takahara


Chest | 1994

Myasthenia Gravis Associated With Small-Cell Carcinoma of the Lung

Jiro Fujita; Ichiro Yamadori; Yasufumi Yamaji; Yoshifumi Yamagishi; Keiichi Takigawa; Jiro Takahara


Journal of Antimicrobial Chemotherapy | 1995

Comparing antimicrobial activity against resistant Pseudomonas aeruginosa using an index for the absence of cross-resistance

Keiichi Takigawa; Jiro Fujita; Kiyoshi Negayama; Guang Xu; Yoshifumi Yamagishi; Hiroshi Miyawaki; Satoko Hojo; Yasufumi Yamaji; Jiro Takahara


Journal of Antimicrobial Chemotherapy | 1993

In-vitro activity of imipenem and amikacin combinations against resistant Pseudomonas aeruginosa

Jiro Fujita; Kiyoshi Negayama; Keiichi Takigawa; Yoshifumi Yamagishi; Yasufumi Yamaji; Koichi Kawanishi; Jiro Takahara

Collaboration


Dive into the Yoshifumi Yamagishi's collaboration.

Top Co-Authors

Avatar

Jiro Fujita

University of the Ryukyus

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shozo Irino

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Akihito Kubo

Aichi Medical University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge